Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Sep 15, 2024 View Original Article
- Bias Rating
- Reliability
- Policy Leaning
- Politician Portrayal